Download Presentation: Proving biosimilars are safely interchangeable with name-branded products

In recent years there has been significant growth in the biosimilar industry, particularly as blockbuster biologics approach the end of their patent protection period. Pharmaceutical companies in emerging markets  (namely Asia, Latin America and Central and Eastern Europe) are investing heavily in biosimilar R&D, and it is predicted that some of these countries will evolve into key players in the …